Pharmaceutical News

RSS

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

Children hospitalized for pneumonia have similar outcomes, including length of stay and costs, regardless of whether they are treated with "big gun" antibiotics such as ceftriaxone or cefotaxime or more narrowly focused antibiotics such as ampicillin or penicillin, according to a Vanderbilt study published in Pediatrics.

10 Dec 2013

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

10 Dec 2013

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

Bone homeostasis requires precise balance between deposition of new bone by osteoblasts and resorption of old bone by osteoclasts. Bone diseases, including osteoporosis and rheumatoid arthritis, are the result of increased osteoclast activity and formation, which allows bone resorption to outpace deposition.

9 Dec 2013

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the United States Food and Drug Administration voted to recommend approval of Takeda's vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease.

9 Dec 2013

TAU researchers discover gene that may predict human responses to specific antidepressants

Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants, but they don't work for everyone. What's more, patients must often try several different SSRI medications, each with a different set of side effects, before finding one that is effective.

9 Dec 2013

New study presents promising results for treatment of multiple myeloma

A new study conducted by scientists from the Dana-Farber Cancer Institute at Harvard Medical School, USA, and Karolinska Institutet, Sweden, presents very promising results for the treatment of the cancer form multiple myeloma. The drug candidate used in the research has been developed by scientists from Karolinska Institutet and a Swedish company following its initial identification at the same university. The findings are so promising that the scientists are teaming up with Harvard to bring the drug to clinical trials on patients.

9 Dec 2013

Taking probiotics during pregnancy has no effect on asthma rate amoung infants

Taking probiotics has health benefits but preventing childhood asthma isn't one of them, shows newly published research led by medical scientists at the University of Alberta.

9 Dec 2013

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute.

9 Dec 2013

People lack knowledge about efficacy of HPV vaccine in preventing cervical cancer

Knowledge about the efficacy of the human papillomavirus vaccine in preventing cervical cancer was lacking in the majority of survey respondents for whom the information would be relevant, according to results presented here at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9.

9 Dec 2013

Researchers identify mechanism implicated in brain cancer and drug that decreases brain tumor growth

Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.

9 Dec 2013

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. Sachdev Sidhu at the University of Toronto and the laboratory of Dr. Joseph Schlessinger of Yale University.

6 Dec 2013

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, announced today that the U.S. Food and Drug Administration has approved XIAFLEX (collagenase clostridium histolyticum, or CCH), an in-office, biologic for the treatment of Peyronie's disease. XIAFLEX is the first and only FDA-approved treatment proven effective for PD in men with a palpable plaque and a curvature deformity of 30 degrees or greater at the start of therapy.

6 Dec 2013

New service helps hospitals and integrated delivery networks expand reach of outpatient pharmacies

At the annual Midyear Clinical Meeting of the American Society of Health-System Pharmacists (ASHP), Cardinal Health will launch a new service that helps hospitals and integrated delivery networks expand the reach of their outpatient pharmacies, while also generating additional revenue and freeing up pharmacist time to drive medication adherence and other quality measures.

6 Dec 2013

Low vitamin D levels: Not a cause but a consequence of ill health

A comprehensive review of the evidence suggests that low vitamin D levels are not a cause but a consequence of ill health, casting strong doubt on the value of vitamin D supplements to protect against acute and chronic disorders such as cancer, cardiovascular disease, diabetes, Parkinson’s disease, and even death.

6 Dec 2013

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Women with moderate to severe menstrual cramps may find relief in a class of erectile dysfunction drugs, according to a team of researchers led by Penn State College of Medicines Richard Legro.

6 Dec 2013

Scientists test affected human nerve cells to foretell efficacy of Alzheimer drugs

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain. Drug testing should therefore be conducted with human nerve cells, conclude the scientists.

6 Dec 2013

NPS MedicineWise publishes set of FAQs on statins and heart disease

With the statins group of cholesterol-lowering medicines continuing to make headlines this week, independent organisation NPS MedicineWise has reviewed the latest clinical evidence and published a set of Frequently Asked Questions on its website addressing people’s key concerns.

6 Dec 2013

Researchers update extensive toxicology database to track information about drugs toxic effects

Sometimes the cure can be worse than the disease. Pharmaceutical drugs are known for their potential side effects, and an important aspect of personalized medicine is to tailor therapies to individuals to reduce the chances of adverse events.

6 Dec 2013

Revolutionary new treatment for crippling hand conditions

A SELF-EMPLOYED decorator whose crippling hand condition has made it virtually impossible to do the simplest of tasks has had his fingers straightened without the need for surgery, thanks to a revolutionary new treatment.

6 Dec 2013

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.

6 Dec 2013

Pharmaceutical News

Children hospitalized for pneumonia have similar outcomes with big gun antibiotics or penicillin

New drug that blocks defective gene can arrest Waldenstrom's Macroglobulinemia in animal models

Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation

FDA advisory committee backs Takeda's vedolizumab for treatment of ulcerative colitis, Crohn's disease

TAU researchers discover gene that may predict human responses to specific antidepressants

New study presents promising results for treatment of multiple myeloma

Taking probiotics during pregnancy has no effect on asthma rate amoung infants

Bortezomib reduces GVHD, boosts survival for patients receiving stem-cell transplants

People lack knowledge about efficacy of HPV vaccine in preventing cervical cancer

Researchers identify mechanism implicated in brain cancer and drug that decreases brain tumor growth

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Auxilium Pharmaceuticals' XIAFLEX gets FDA approval for treatment of Peyronie's disease

New service helps hospitals and integrated delivery networks expand reach of outpatient pharmacies

Low vitamin D levels: Not a cause but a consequence of ill health

Women with moderate to severe menstrual cramps may find relief in erectile dysfunction drugs

Scientists test affected human nerve cells to foretell efficacy of Alzheimer drugs

NPS MedicineWise publishes set of FAQs on statins and heart disease

Researchers update extensive toxicology database to track information about drugs toxic effects

Revolutionary new treatment for crippling hand conditions

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News